{"id":"NCT00289783","sponsor":"GlaxoSmithKline","briefTitle":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","officialTitle":"A Phase III, Randomized, Multinational Study, Double-blinded for the Immunogenicity and Consistency Evaluation of 3 Hib-MenCY-TT Vaccine Lots and Single-blinded and Controlled for the Evaluation of Safety and Immunogenicity of GSK Biologicals' Haemophilus Influenzae Type b and Neisseria Meningitidis Serogroups C and Y-tetanus Toxoid Conjugate Vaccine Combined (Hib-MenCY-TT) Compared to Monovalent Hib Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02-22","primaryCompletion":"2007-08-27","completion":"2008-02-26","firstPosted":"2006-02-10","resultsPosted":"2012-08-06","lastUpdate":"2018-08-24"},"enrollment":4441,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Haemophilus Influenzae Type b","Neisseria Meningitidis"],"interventions":[{"type":"BIOLOGICAL","name":"GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"ActHIB","otherNames":[]},{"type":"BIOLOGICAL","name":"PedvaxHIB","otherNames":[]},{"type":"BIOLOGICAL","name":"Pediarix","otherNames":["Infanrix penta"]},{"type":"BIOLOGICAL","name":"Prevnar","otherNames":[]},{"type":"BIOLOGICAL","name":"M-M-R II","otherNames":[]},{"type":"BIOLOGICAL","name":"Varivax","otherNames":[]}],"arms":[{"label":"Menhibrix A Group","type":"EXPERIMENTAL"},{"label":"Menhibrix B Group","type":"EXPERIMENTAL"},{"label":"Menhibrix C Group","type":"EXPERIMENTAL"},{"label":"Menhibrix Group","type":"EXPERIMENTAL"},{"label":"ActHIB Group","type":"ACTIVE_COMPARATOR"}],"summary":"This study evaluates the immunogenicity and consistency of 3 Hib-MenCY-TT vaccine lots and the safety and immunogenicity of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine, when each are co-administered with Pediarix® to healthy infants at 2, 4, and 6 months of age. The study will also evaluate the safety and immunogenicity of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine, when each are co-administered with M-M-R® II and Varivax® at 12 to 15 months of age.","primaryOutcome":{"measure":"Anti-Polyribosyl Ribitol Phosphate (PRP) Antibody Concentrations","timeFrame":"One month after primary vaccination","effectByArm":[{"arm":"Menhibrix A Group","deltaMin":10.17,"sd":null},{"arm":"Menhibrix B Group","deltaMin":11.424,"sd":null},{"arm":"Menhibrix C Group","deltaMin":11.438,"sd":null},{"arm":"Menhibrix Group","deltaMin":11.021,"sd":null},{"arm":"ActHIB Group","deltaMin":6.463,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":21},"locations":{"siteCount":93,"countries":["United States","Australia","Mexico"]},"refs":{"pmids":["21806393","21624883","22617844","22327493"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":126,"n":3136},"commonTop":["Irritability","Pain","Drowsiness","Redness","Loss of appetite"]}}